Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 1, 2013, Pages 119-124

  Russell, Eric ^a   Luk, Francis ^b   Manocha, Sonia ^b   Ho, Tung ^b   O'Connor, Carolyn ^b   Hussain, Humaira ^b  

^a Christiana Care   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anti TNF; Infliximab; Remicade; Sarcoid; Sarcoidosis; Tumor necrosis factor inhibitor

Indexed keywords

CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LONG TERM CARE; LUNG SARCOIDOSIS; MALE; PAPILLOMAVIRUS INFECTION; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; RETROSPECTIVE STUDY; SARCOIDOSIS; SEPSIS; SIDE EFFECT; SINUSITIS; SYMPTOM; TREATMENT FAILURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ADVERSE EVENTS; AE; ANTI-TNF; CARBON MONOXIDE DIFFUSING CAPACITY; CENTRAL NERVOUS SYSTEM; CNS; COMPUTERIZED TOMOGRAPHY; CT; DLCO; FEV1; FORCED EXPIRATORY VOLUME IN 1S; FORCED VITAL CAPACITY; FVC; HCQ; HPV; HUMAN PAPILLOMA VIRUS; HYDROXYCHLOROQUINE; IFX; INFLIXIMAB; LN; LYMPH NODE; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MRI; MTX; PFT; PPD; PULMONARY FUNCTION TEST; PURIFIED PROTEIN DERIVATIVE; REMICADE; SARCOID; SARCOIDOSIS; TLC; TNF; TOTAL LUNG CAPACITY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETREATMENT; SARCOIDOSIS; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME;

EID: 84881542736     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.10.008     Document Type: Article

References (32)

1. Marques L., Zheng L., Poulakis N., Guzman J., Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999, 159:508-511.
2. Fehrenbach H., Zissel G., Goldmann T., Tschernig T., Vollmer E., Pabst R., Müller-Quernheim J. Alveolar macrophages are the main source for tumor necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003, 21(3):421-428.
3. Judson M.A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999, 115:1158-1165.
4. Baughman R.P., Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999, 54:742-746.
5. Jones E., Callen J.P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990, 23:487-489.
6. Muller-Quernheim J., Kienast K., Held M., Pfeifer S., Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999, 14:1117-1122.
7. Doty J.D., Mazur J.E., Judson M.A. Treatment of corticosteroid-resistant neurosarcoidosis with a short- course cyclophosphamide regimen. Chest 2003, 124:2023-2026.
8. Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997, 155:1665-1669.
9. Judson M.A., Silvestri J., Hartung C., Byars T., Cox C.E. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:51-57.
10. Lipsky P.E., van der Heijde D.M.F.M., Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
11. Baughman R.P., Iannuzzi M. Tumor necrosis factor in sarcoidosis and its potential for targeted therapy. Biodrugs 2003, 17:425-431.
12. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359:1541-1549. the ACCENT I Study Group.
13. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
14. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double blind trial. Lancet 2005, 366:1367-1374. for the EXPRESS study investigators.
15. Kavanaugh A., Krueger G.G., Beutler A., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505. for the IMPACT 2 Study Group.
16. Van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
17. Menon Y., Cucurull E., et al. Interferon-α associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004, 328:173-175.
18. Fouchier S.M., Moller G.M., et al. Successful treatment with infliximab of a patient with refractory sarcoidosis. Ned Tijdschr Geneeskd 2004, 148:2446-2450.
19. Ulbricht K.U., Stol M., et al. Successful tumor necrosis factor-α blockade treatment in therapy resistant sarcoidosis. Arthritis Rheum 2003, 48:3542-3543.
20. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18:310.
21. Yee A.M., Pochapin M.D. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 2001, 135:27-31.
22. Pritchard C., Nadarajah K. Tumor necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004, 63:318-320.
23. Roberts S.D., Wilkes D.S., et al. Refractory sarcoidosis responding to infliximab. Chest 2003, 124(5):2028-2031.
24. Doty J.D., Mazur J.E., Judson M.A. Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064-1071.
25. Utz J.P., Limper A.H., Kalra S. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124(1):177-185.
26. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164:1885-1889.
27. Rybicki B.A., Major M., Popovich J., Maliarik M.J., Iannuzzi M.C. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997, 145:234-241.
28. Judson M.A., Baughman R.P., Costabel U., et al. Efficacy of infliximab in extra-pulmonary sarcoidosis: results from a randomized trial. Eur Respir J 2008, 31(6):1189-1196.
29. Baughman R.P., Drent M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174:795-802.
30. Panselinas E., Rodgers J.K., Judson M.A. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009, 14(4):522-528.
31. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
32. Borg G. Psychological bases of perceived exertion. Med Sci Sports Exercise 1982, 14:377-381.